Preferred Label : immunotherapy, adoptive;

MeSH definition : Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314);

MeSH synonym : adoptive immunotherapies; immunotherapies, adoptive cellular; immunotherapy, adoptive cellular; adoptive cellular immunotherapy; adoptive immunotherapy; immunotherapies, adoptive; cellular immunotherapy, adoptive; adoptive cellular immunotherapies; cellular immunotherapies, adoptive;

MeSH hyponym : CAR T-Cell Therapy; CAR T Cell Therapy; CAR T-Cell Therapies; T-Cell Therapies, CAR; T-Cell Therapy, CAR; Therapies, CAR T-Cell; Therapy, CAR T-Cell;

MeSH annotation : IM; do not use /util except by MeSH definition; for CAR T-Cell Therapy, coordinate with RECEPTORS, CHIMERIC ANTIGEN;

Wikipedia link : https://en.wikipedia.org/wiki/Adoptive immunotherapy;

Details


Main resources

You can consult :

Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)

https://www.afmps.be/fr/news/les_medicaments_de_therapie_innovante_non_reglementes_presentent_de_graves_risques_pour_la
2025
false
false
false
Belgium
French
innovative therapies
risk
patient safety
pharmacovigilance note
Dendritic Cell Therapy
immunotherapy, adoptive
dendritic cells
legislation, drug
europe
belgium

---
https://ansm.sante.fr/actualites/retour-dinformation-sur-le-prac-de-janvier-2024-8-11-janvier
2024
false
false
false
France
French
risk management
valproic acid
Male
Neurodevelopmental Disorders
Chimeric antigen receptor T-cell therapy
genetic therapy
Secondary Carcinoma
Chimeric Antigen Receptor Therapy
immunotherapy, adoptive
pharmacovigilance note

---
https://ansm.sante.fr/tableau-acces-derogatoire/yescarta-0-4-2-x-108-cellules-dispersion-pour-perfusion#
2024
false
false
false
France
French
axicabtagene ciloleucel
axicabtagene ciloleucel
biological products
Antineoplastic Agents, Immunological
Recurrent High Grade B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
adult
Refractory High Grade B-Cell Lymphoma
drug information
immunotherapy, adoptive
antigens, CD19

---
https://www.has-sante.fr/jcms/p_3262244/fr/yescarta-axicabtagene-ciloleucel
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
axicabtagene ciloleucel
adult
lymphoma, large B-Cell, diffuse
mediastinal neoplasms
recurrence
Primary mediastinal (thymic) large B-cell lymphoma (disorder)
Primary Mediastinal Large B-Cell Lymphoma
infusions, intravenous
Anti-CD19 CAR T Cells Preparation
Recurrent Primary Mediastinal Large B-Cell Lymphoma
antigens, CD19
Receptors, Chimeric Antigen
t-lymphocytes
evaluation of the transparency committee
axicabtagene ciloleucel
antigens, CD19
immunotherapy, adoptive
immunotherapy, adoptive

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/avis-sur-laxicabtagene-ciloleucel-pour-le-traitement-des-lymphomes-a-grandes-cellules-b-recidivants-ou-refractaires.html
2019
false
true
false
false
Canada
Diffuse large B-cell lymphoma recurrent
Diffuse large B-cell lymphoma refractory
axicabtagene ciloleucel
technical report
axicabtagene ciloleucel
lymphoma, large B-Cell, diffuse
immunotherapy, adoptive
antigens, CD19

---
http://www.john-libbey-eurotext.fr/fr/revues/medecine/bdc/e-docs/00/03/F9/68/resume.md?type=text.html
2003
France
French
melanoma
lymphocytes, tumor-infiltrating
melanoma
immunotherapy, adoptive
immunotherapy, adoptive
immunotherapy, adoptive
lymphocytes, tumor-infiltrating
journal article
french abstract

---
Nous contacter.
04/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.